Immunotherapy Effective in Metastatic Prostate Cancers With Specific Markers of Immune Activation
April 03, 2020
April 03, 2020
HOUSTON, Texas, April 3 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 1:
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at The University of Texas MD Anderson Cancer Cen . . .
Although metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T-cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at The University of Texas MD Anderson Cancer Cen . . .